期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替罗非班的不同给药途径对急性ST段抬高型心肌梗死急诊PCI术中无复流的疗效对比 被引量：6

下载PDF
导出
摘要 目的观察经指引导管和经OTW(over the wire)球囊中心腔注射替罗非班对急性ST段抬高型心肌梗死(STEMI)急诊经皮冠状动脉介入治疗(PCI)术中无复流的疗效。方法连续入选2006年1月至2011年5月在我院确诊为急性STEMI并接受急诊PCI治疗,术中出现无复流的患者96例,随机分为经OTW球囊注射替罗非班组49例和对照组经指引导管注射替罗非班47例。通过对比较两组患者首次注射药物后、PCI结束前末次冠状动脉造影图像;评估心肌梗死溶酸试验(TIMI)和矫正的TIMI帧数(cTFC)及TIMI心肌组织灌注分级(TMPG)、超敏c-反应蛋白(hs-CRP)及60d主要不良心脏事件(major adverse cardial event,MACE)。结果经OTW球囊注射替罗非班组较对照组患者用药后首次和PCI结束前末次造影结果均显示:OTW组术后梗死的相关动脉(IRA)的TIMI3级和TMPG3级血流发生率明显高于了对照组;cTFC的下降出现了明显的差异具有统计学意义;用药后5d,hs-CRP也明显的下降出现了明显的差异具有统计学意义。与对照组比较60dMACE差异无统计学意义。结论对于急性STEMI患者行急诊PCI术中出现无复流患者,经OTW球囊注射替罗非班可更好改善冠状动脉血流,改善心肌水平再灌注状态、抑制炎性反应。
作者 赵学森 依仁科 董志
机构地区 辽宁省抚顺市矿务局总医院循环一病房
出处 《中国医药指南》 2012年第20期136-138,共3页 Guide of China Medicine
关键词 无复流 替罗非班 OTW球囊 ST段抬高型心肌梗死 急诊PCI
分类号 R542.22 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1Pasceri V,Patti G,Di Sciaacio G.Prevention of myocardial damage during coronary intervention[J].Cardiovasc Hematol Disord Drug Targets,2006,6(2):77-83.
  • 2Morishima I,Stone T,Okumura K,et al.Angiogrephic no-reflow phenomenon as apredicter of adverse long-term outcome in patinents treated with percutaneous transluminal coronary angioplasty for first acutemyocardial infarction[J].J Am Coll Cardio,2000,36(4):12022-12029.
  • 3杨新春,徐立,王乐丰,葛永贵,王红石,丁枭伟,王文君,邹阳春,李惟铭,刘宇.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究[J].中国循环杂志,2006,21(1):4-7. 被引量：91
  • 4Gibson CM,Cannon CP,Muphy SA,et a1.Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs[J].Circulation,2000,101(2):125-130.
  • 5Shade MS,Tak WK.No-reflow phenomenon following percata-neout coronary intervention:an uncommon complicatin[J].Angi-ology,2000,51(3):247-252.
  • 6Antman EM,Anbe DT,Armstrong PW,et al.Aee/Att a guidelines for the management of patients SF elevation myocardial infarction-executive summary.A report of the amorican college of cardiology/american heart association task force on practice guidelines(Writing committee to revise the1999guidelines for the management of patients with a cute myocardial infaretion)[J].J Am Coll Cardiol,2004,44(3):671-719.
  • 7MOVAHED M R,BuTMAN s M.The pathogenesisand treatment of no-flow occurring during percutaneous coronary intervention[J].Cardiovasc RevaseMed,2008,9:56-61.
  • 8Celik T,Iyisoy A,Kursaklioglu H,et a1.The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction[J].Coron Artery Dis,2005,169(3):293-299.

二级参考文献12

  • 1Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation, 2002,105 : 656-662.
  • 2Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein Ⅱ b/Ⅲ a blockade with primary PTCA Organization and Randomized Trial ( RAPPORT ). Circulation, 1998,98 : 734-741.
  • 3Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344:1895-1903.
  • 4Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acuete myocardial infarction. N Eng J Med, 2002, 346 : 957-966.
  • 5Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blockade on recovery flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infction. Circulation, 1998, 98 : 2695-2701.
  • 6Petronioa AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Euro Heart Journal, 2003, 24: 67-76.
  • 7The RESTORE Investigators. Effects of platelet glycoprotein Ⅱ b/Ⅲ a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96: 1445-1453.
  • 8Lincoff AM. Trial of platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonists during percutaneous coronary revascularization. Am J Cardiol, 1998, 82:36-42.
  • 9Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol, 2004, 94:35-39.
  • 10Gibson CM, Christopher PC, William LD, et al. TIMI frame count : A quantitative method of assessing coronary artery flow. Circulation, 1996,93 : 879-888.

共引文献90

同被引文献49

  • 1卢竞前,杨锋,李易,李建美,吕云,洪云飞,李玉,张荣华,吴燕.国产替罗非班在易化PCI治疗急性心肌梗死中应用观察[J].中国急救医学,2006,26(5):384-385. 被引量：2
  • 2丛洪良,杜纪兵,齐学艳,张梅,王伟,陈树涛,周长钰,李广平,黄体钢.急性心肌梗死患者经皮冠脉介入术后无/慢复流发生与炎症[J].中华高血压杂志,2007,15(6):485-488. 被引量：16
  • 3Montalescot G,Barragan P,Wittenbery O,et al.For the ADMIRAL investigators.Platelet glycopretionⅡb/Ⅲa inhibition with coronary stenting for acute myocardial infarction[J].N Eng J Med,2001,345(21):1895-1903.
  • 4The TIMI study group.The Thrombolysis in Myocardial Infarction(TIMI)Trial-Phase I Findings[J].N Engl J Med,1985,312(14):932-936.
  • 5Rezkalla SH,Kloner R A.No-reflow phenomenon[J].Circulation,2002,105(5):656-662.
  • 6Juergens CP,White HD,Belardi JA,et al.Amulticenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement[J].Clin Ther,2002,24(8):1332-1344.
  • 7Kopetz VA, PennoM A, Hoffmann P, et al. Potential mecha- nisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon insight from a plas- ma proteomic approach[J]. Int J Cardiol ,2012,156( 1 ) :84 -91.
  • 8Wozakowska - Kaplon B, Niedziela J, Krzyzak P, et al. Clini- cal manifestations of slow corona y flow from acute coronary syndrome to serious arrhythmia[J].Cardiol J,2009,16 (5) : 462 - 468.
  • 9汪兵,吴继雄.替罗非班在冠心病介入治疗围手术期的应用及研究进展[J].安徽医学,2013,34(4):686-687.
  • 10薛涛,张玉东,陈韵岱.急诊冠状动脉介入治疗后无复流的机制以及防治策略[J].心血管病学进展,2009,30(2):250-253. 被引量：11

引证文献6

二级引证文献44

中国医药指南
2012年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部